JP2012046489A5 - - Google Patents

Download PDF

Info

Publication number
JP2012046489A5
JP2012046489A5 JP2011151340A JP2011151340A JP2012046489A5 JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5 JP 2011151340 A JP2011151340 A JP 2011151340A JP 2011151340 A JP2011151340 A JP 2011151340A JP 2012046489 A5 JP2012046489 A5 JP 2012046489A5
Authority
JP
Japan
Prior art keywords
cancer
cells
virus
use according
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011151340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012046489A (ja
Filing date
Publication date
Priority claimed from AU2002953436A external-priority patent/AU2002953436A0/en
Application filed filed Critical
Publication of JP2012046489A publication Critical patent/JP2012046489A/ja
Publication of JP2012046489A5 publication Critical patent/JP2012046489A5/ja
Pending legal-status Critical Current

Links

JP2011151340A 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法 Pending JP2012046489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002953436 2002-12-18
AU2002953436A AU2002953436A0 (en) 2002-12-18 2002-12-18 A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004559490A Division JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Publications (2)

Publication Number Publication Date
JP2012046489A JP2012046489A (ja) 2012-03-08
JP2012046489A5 true JP2012046489A5 (enExample) 2012-10-11

Family

ID=30004521

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法
JP2011151340A Pending JP2012046489A (ja) 2002-12-18 2011-07-08 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004559490A Pending JP2006517189A (ja) 2002-12-18 2003-12-18 直接的なピコルナウイルス媒介腫瘍崩壊による対象における悪性腫瘍の治療方法

Country Status (11)

Country Link
US (2) US7485292B2 (enExample)
EP (1) EP1581257B1 (enExample)
JP (2) JP2006517189A (enExample)
KR (1) KR101171295B1 (enExample)
CN (2) CN1784242B (enExample)
AU (1) AU2002953436A0 (enExample)
CA (1) CA2510227C (enExample)
ES (1) ES2463678T3 (enExample)
NZ (1) NZ541230A (enExample)
WO (1) WO2004054613A1 (enExample)
ZA (1) ZA200505389B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
KR101295733B1 (ko) 2004-08-20 2013-08-13 비랄리틱스 리미티드 혈액암의 치료방법 및 조성물
CN102166218A (zh) * 2005-01-17 2011-08-31 溶瘤病毒有限公司 治疗肿瘤的方法和组合物
WO2013157648A1 (ja) 2012-04-19 2013-10-24 国立大学法人九州大学 医薬組成物
EP2826856B9 (en) 2013-07-16 2016-05-04 Sia Latima Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
CN103981152B (zh) * 2014-04-16 2015-01-21 武汉博威德生物技术有限公司 一种柯萨奇病毒及其制备抗肿瘤药物之应用
MX428707B (es) 2016-09-27 2025-11-13 Sator Therapeutics LLC Virus oncoliticos optimizados y usos de los mismos.
WO2018182014A1 (ja) 2017-03-31 2018-10-04 久修 緒方 腫瘍溶解性ウイルスの増殖方法及び抗腫瘍剤
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54113421A (en) * 1978-02-24 1979-09-05 Fumiaki Taguchi Large scale cultivation of virus
US5585254A (en) 1987-08-21 1996-12-17 University Of Colorado Foundation, Inc. Autonomous parvovirus gene delivery vehicles and expression vectors
WO1990012087A1 (en) 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
CA2051289C (en) 1990-09-14 2002-11-26 Robert L. Martuza Viral mediated destruction of neoplastic cells
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115991A1 (en) 1991-06-24 1993-01-07 Eckard Wimmer De novo cell-free synthesis of picornavirus
CA2113990A1 (en) 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5529774A (en) 1991-08-13 1996-06-25 The Regents Of The University Of California In vivo transfer of the HSV-TK gene implanted retroviral producer cells
SE503225C2 (sv) 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US6071742A (en) 1997-03-05 2000-06-06 Board Of Regents Of The University Of Nebraska Coxsackie virus as a vector for delivery of anti-inflammatory cytokines
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP1905304A3 (en) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1061806A4 (en) 1998-03-12 2001-09-12 Univ Pennsylvania PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES
US6060316A (en) 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
US6264940B1 (en) 1998-08-05 2001-07-24 The Research Foundation Of State University Of New York Recombinant poliovirus for the treatment of cancer
EP1150696B1 (en) 1999-02-05 2006-05-10 Arch Development Corporation Genetically engineered herpes virus for the treatment of tumours
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
AU2005201079C1 (en) 1999-04-15 2008-11-06 Wellstat Biologics Corporation Treatment of neoplasms with viruses
EP1067188A1 (en) 1999-07-08 2001-01-10 Introgene B.V. Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 Coxsacki adenovirus receptor (CAR)
DE19939095A1 (de) 1999-08-18 2001-02-22 Univ Eberhard Karls Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer
AU782402B2 (en) 1999-09-17 2005-07-28 Wellstat Biologics Corporation Oncolytic virus
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
WO2001036650A2 (en) 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU770517B2 (en) 1999-11-25 2004-02-26 Viralytics Limited A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2004202292B2 (en) 1999-11-25 2007-06-14 Viralytics Limited Method of Treating a Malignancy in a Subject
JP4810042B2 (ja) 2000-01-21 2011-11-09 バイオヴェックス リミテッド ヘルペスウイルス株
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020071832A1 (en) 2000-06-01 2002-06-13 Yuman Fong Use of mutant herpes viruses and anticancer agents in the treatment of cancer
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
US20020146828A1 (en) * 2001-01-05 2002-10-10 John Hural Microparticles and methods for delivery of recombinant viral vaccines
WO2002087625A1 (en) 2001-05-02 2002-11-07 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2140879A1 (en) 2001-05-09 2010-01-06 M'S Science Corporation Composition and method for treating cancer using herpes virus
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
CA2352439A1 (en) 2001-07-17 2003-01-17 Patrick W. K. Lee Engineering oncolytic viruses
JP2004536607A (ja) 2001-07-23 2004-12-09 オニックス ファーマシューティカルズ，インコーポレイティド 標的化されたヒト癌細胞において選択的に複製するウイルス変異体
AU2003216502B2 (en) 2002-03-01 2008-04-10 Sloan-Kettering Institute For Cancer Research Prevention of recurrence and metastasis of cancer
WO2003082200A2 (en) 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
NZ536102A (en) 2002-05-09 2008-01-31 Oncolytics Biotech Inc Oncolytic viruses, in particular reovirus, for reducing pain associated with proliferative disorders, particularly with the growth of a solid tumour mass
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005002607A2 (en) 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
WO2005007824A2 (en) 2003-07-08 2005-01-27 Arizona Board Of Regents Mutants of vaccinia virus as oncolytic agents
DK1668025T3 (da) 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
CN101027394A (zh) 2004-03-11 2007-08-29 维若塔歌私人有限公司 修饰的溶瘤病毒
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006047301A2 (en) 2004-10-21 2006-05-04 The Penn State Research Foundation Parvovirus methods and compositions for killing neoplastic cells

Similar Documents

Publication Publication Date Title
Roy et al. Lycorine: A prospective natural lead for anticancer drug discovery
Qian et al. Berberine reverses breast cancer multidrug resistance based on fluorescence pharmacokinetics in vitro and in vivo
NZ717490A (en) Methods of treating cancer
Bouche Compression and entrapment neuropathies
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
JP2014530873A5 (enExample)
JP2013155188A5 (enExample)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
HK1210699A1 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
JP2018522028A5 (enExample)
JP2015507020A5 (enExample)
JP2015506352A5 (enExample)
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
JP2017516842A5 (enExample)
CN103239464A (zh) 淫羊藿次苷ii在制备肿瘤化疗药物增敏剂中的用途
JP2015529664A5 (enExample)
Cui et al. The Crosstalk Between Epithelial-Mesenchymal Transition and Anoikis Resistance: A New Perspective of Traditional Chinese Medicine to Prevent Tumor Metastasis
Mierzejewska et al. Novel evidence that hematopoietic stem/progenitor cells (HSPCs) are mobilized during hemolysis in an erythrocyte lysis-derived, sphingosine-1-phosphate (S1P)-dependent manner—the crucial involvement of complement cascade (CC) activation and attenuation of CXCR4 retention signaling
Marzuillo et al. Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia
Elhaj et al. Male breast cancer patients: a retrospective study of patients characteristics and treatment outcome at the National Cancer Institute (NCI-UG)-Central Sudan
齐鲁楠 Vasculogenic mimicry in human hepatocellular carcinoma
Zhang et al. Effects of myxoma virus on gliomas of rats models in vivo
Zhou et al. Selective bladder preservation in muscle-invasive bladder cancer by transurethral resection combined with intravesical instillation therapy: analysis of clinical effect in the elderly
Jin et al. Treatment Performance Measures Affect Clinical Outcomes in Patients With Acute Systolic Heart Failure
Waziry et al. Stain Modulation of Oncolytic Vesicular Stomatitis Virus